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Bacterial biofilms are three-dimensional structures containing bacterial cells enveloped
in a protective polymeric matrix, which renders them highly resistant to antibiotics and
the human immune system. Therefore, the capacity to make biofilms is considered
as a major virulence factor for pathogenic bacteria. Cold Atmospheric Plasma (CAP)
is known to be quite efficient in eradicating planktonic bacteria, but its effectiveness
against biofilms has not been thoroughly investigated. The goal of this study was to
evaluate the effect of exposure of CAP against mature biofilm for different time intervals
and to evaluate the effect of combined treatment with vitamin C. We demonstrate
that CAP is not very effective against 48 h mature bacterial biofilms of several
common opportunistic pathogens: Staphylococcus epidermidis, Escherichia coli, and
Pseudomonas aeruginosa. However, if bacterial biofilms are pre-treated with vitamin C
for 15 min before exposure to CAP, a significantly stronger bactericidal effect can be
obtained. Vitamin C pretreatment enhances the bactericidal effect of cold plasma by
reducing the viability from 10 to 2% in E. coli biofilm, 50 to 11% in P. aeruginosa, and 61
to 18% in S. epidermidis biofilm. Since it is not feasible to use extended CAP treatments
in medical practice, we argue that the pre-treatment of infectious lesions with vitamin C
prior to CAP exposure can be a viable route for efficient eradication of bacterial biofilms
in many different applications.
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INTRODUCTION
In bacterial biofilms, bacteria arrange themselves in three-dimensional structures, which adhere
to the surface. Within a biofilm, bacteria interact with each other and an extracellular polymeric
matrix provides the community with protection from hostile environment and exposure of
antimicrobial agents (Hoiby et al., 2010; Zhou et al., 2015). The extracellular matrix is an important
factor in antibiotic resistance. It acts primarily in slowing down the penetration of antibiotics to
the cells inside the biofilm, thus reducing the effective dose of antibiotics delivered to the cells.
The decreased rate of diffusion of antibiotics into the biofilm enables cellular expression of genes
mediating resistance to antibiotics to be activated in the deeper layers of the biofilm (Donlan and
Costerton, 2002; Hoiby et al., 2010). Slow penetration of antibiotics inside the matrix material
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gradually lowers the growth rate of biofilm-associated bacterial
cells, which slows down the intake of antibiotics. In addition,
the cells killed by the antibiotic in the upper layers of the
biofilm “dilute” antibiotics on a per cell basis (Donlan and
Costerton, 2002; Bagge et al., 2004; Mai-Prochnow et al.,
2008). Biofilms structures also naturally limit the penetration
of nutrients to the inner cell layers, and the lack of nutrients
results in persistent cells that have higher tolerance to antibiotics
(Costerton et al., 1999; Donlan and Costerton, 2002). It has also
been proposed that biofilms cannot be completely eradicated due
to the survival of persistent cells which accumulate mutations
leading to antibiotic resistance (Lewis, 2007). Bacterial cells in
biofilms also show increased resistance to the host immune
system (Leid et al., 2005; Cerca et al., 2007). Bacterial biofilms
are thus recognized as an important cause of chronic infections,
including biofilm formation on medical devices, in wounds,
and in immunocompromised patients (Costerton et al., 1999;
Bjarnsholt et al., 2008). Common bacteria, such as Staphylococcus
epidermidis, Escherichia coli, and Pseudomonas aeruginosa, that
are generally opportunistic or pathogenic, can cause severe
chronic infections in immunocompromised individuals (Kaper
et al., 2004; de Bentzmann and Plesiat, 2011). The inappropriate
use of antibiotics can cause bacteria to develop resistance,
rendering infections by antibiotic resistant bacteria which is a
major emerging threat (Ventola, 2015a). According to WHO,
the global threat of antibiotic resistance is likely to usher a
post-antibiotics era (Kostakioti et al., 2013; WHO, 2014). Thus,
in addition to managing the usage of antibiotics, there is a
significant need of novel approaches for treatment of bacterial
infections (Ventola, 2015b). When it comes to bacterial biofilms,
antibiotics or other known antimicrobial agents are not strong
enough to eradicate them completely (Hoiby et al., 2010; Hoiby,
2011). In this context, the use of a combined therapeutic strategy
is recommended to obtain a strong bactericidal effect against
bacterial biofilms.
Plasma has been defined as the fourth state of matter, in
addition to solid, liquid, and gas (Tendero et al., 2006). The
plasma state can be described as an ionized gas, where ionization
is obtained by adding energy to the gas. In case of medical
applications, the ionizing energy most commonly comes from
electricity (Tendero et al., 2006). For plasma to be used in
medicine, it has to be generated at atmospheric pressure and
the gas temperature must be suitable for treatment of living
tissue, with minimal damage to surrounding healthy tissue
(Laroussi, 2009). Plasma used in medicine is therefore often
called cold atmospheric plasma (CAP; Graves, 2014). In medical
treatments, plasma exposure is indirect or remote, where the
plasma itself does not come into contact with the tissue, rather,
it is an afterglow of the ionized gas (Kong et al., 2009; Bárdos
and Baránková, 2010). These plasma sources are called remote
plasma jets. In these devices the operating gas flows between
two coaxial electrodes, an inner electrode usually powered with
radiofrequency (RF) and an outer one grounded. One or both
electrodes can be covered with a dielectric barrier (DBD),
resulting in an ionized gas jet out of the equipment’s nozzle
(Bárdos and Baránková, 2010). CAP has received considerable
attention in microbiology due to its high bactericidal activity
(Maisch et al., 2012; Mai-Prochnow et al., 2014). The main
killing mechanism of CAP is the generation of reactive oxygen
and nitrogen species (RONS), which have an adverse effect on
the cellular biochemistry: damaged proteins and nucleic acids
(Joshi et al., 2010; de Geyter and Morent, 2012). In addition,
CAP has been shown to have low toxicity toward healthy
human cells (Joshi et al., 2010; de Geyter and Morent, 2012).
The current CAP-based treatments are not efficient enough in
eradicating persistent bacterial biofilms, and we therefore looked
for a combined therapeutic strategy which could complement
it. Vitamin C, which is a common food additive and can
be safely used in medical treatment, is known to be a ROS-
generating agent, and can kill some bacterial species (Vilchèze
et al., 2013). We investigated if vitamin C pre-treatment could
enhance the antibacterial efficacy of CAP at different exposure
times on a 48 h bacterial biofilm. The study has been conducted
on a non-pathogenic Gram-positive model bacterium Bacillus
subtilis, and three facultative pathogens: Gram-negative E. coli
and P. aeruginosa, and Gram-positive S. epidermidis. The non-
pathogenic B. subtilis was very sensitive to CAP alone, but for the
three pathogens with CAP-resistant biofilms, the pre-treatment
with vitamin C dramatically increased the bactericidal effect.
MATERIALS AND METHODS
CAP Source
For this study we used the CE certificated atmospheric pressure
plasma jet kINPen 11 (neoplas control GmbH, Greifswald,
Germany). The plasma source consists of an operating device
and a hand-held pen. Inside the pen is a ceramic capillary
with a centered high-frequency electrode (1 MHz, 2–3 kV).
At the end of the pen is a grounded ring electrode that
surrounds the capillary. When the working gas flows through
the capillary, it gets ionized between the electrodes, creating a
plasma-jet expanding out of the nozzle of the hand-held pen. The
discharge is generated with a frequency of 5 kHz. The plasma
pen was operated with 4.5 standard liters per minute (SLM) of
compressed air (2.5 bars).
Bacterial Biofilm Cultivation and CAP
Exposure
A total of 4 bacterial strains were used in this study. B. subtilis
NCIB 3610 and E. coli UTI 89 were grown in LB broth, whereas,
P. aeruginosa and S. epidermidis were grown in tryptic soy broth
(TSB). Briefly, overnight grown bacterial culture was diluted to
make a 2–5× 106 CFU/mL suspension in LB broth for B. subtilis
and E. coli and in TSB broth for P. aeruginosa and S. epidermidis.
Two hundred microliters of the diluted bacterial suspension was
then loaded on 15 mm glass cover slips and incubated for 24 h at
37◦C without agitation. After a 24-h incubation, the old culture
medium was replaced by equal volume of fresh medium, and the
sample was incubated for another 24 h. The 48 h old biofilms
were exposed to CAP for 5, 10, 15, 30, and 60 min (as indicated in
the figure legends), with a 15mmdistance between the nozzle and
the sample. To evaluate the effect of vitamin C pre-treatment, 48
h biofilms were carefully washed with sterile water to remove the
free floating bacteria and treated with 200 µl of 5 mM of vitamin
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C (for vitamin C and vitamin C+CAP) or same volume of sterile
water (for control and CAP) for 15 min followed by a 5-min CAP
exposure. Ascorbic acid was purchased from sigma Aldrich (St.
Louis, MO, USA).
Colony Forming Units (CFU) Counting
The viability of bacteria in the biofilms was analyzed by CFU
counting. The biofilms were detached from the coverslip by
treating with 5 ml of 0.89%NaCl solution, followed by sonication
for 10 s (15 s for S. epidermidis) to release the bacteria from
the glass coverslip. This resulted in a homogenous bacterial
suspension in NaCl solution. Homogeneity of the suspension
was observed using a brightfield microscope (Supplementary
Figure 1). Homogenized suspension (100 µl) was diluted serially
and plated on LB agar plates, which were then incubated
overnight at 37◦C. The number of colonies was then counted
and the total number of CFU in 5 ml NaCl was calculated,
determining the number of surviving bacteria in the samples.
Live/Dead Staining
The biofilms were stained using the Live/Dead BacLight Viability
kit L13152, (Invitrogen, Molecular Probes, Inc. Eugene, OR,
USA) to determine the proportion of live and dead cells. Bacterial
cells with intact cell membranes emit green fluorescence while
dead or damaged bacterial cells emit red fluorescence. The
staining was performed at room temperature in the dark, for
20 min, using a mixture of 6.0 µM SYTO 9 and 30 µM
potassium iodide. Fluorescence microscopic imaging of the
biofilms was performed using a Zeiss fluorescence microscope
(Axio Imager.Z2m Carl Zeiss, Zena, Germany).
Scanning Electron Microscopy (SEM)
For scanning electron microscopy (SEM), the biofilms were fixed
with 3% glutaraldehyde solution for 2 h and dehydrated in graded
series of ethanol concentrations (30, 40, 50, 60, 70, 80, and 90%)
for 15 min in each solution, and finally with 100% ethanol for 20
min. The dehydrated biofilms were dried at room temperature
and coated with gold (5 nm) before SEM imaging. SEM imaging
was performed with Supra 60 VP (Carl Zeiss AG).
Statistical Analysis
All experiments were performed in biological triplicates and
presented as the means ± standard deviations. Intergroup
differences were estimated by one-way analysis of variance
(ANOVA), followed by a post-hoc multiple comparison (Tukey)
test to compare the multiple means. Values were considered to be
statistically significant when the P-value was<0.05.
RESULTS
Effect of CAP Exposure on the Viability of
Bacterial Biofilms
Forty-eight hours old biofilms of B. subtilis, E. coli, P. aeruginosa,
and S. epidermidis were prepared as described in materials and
methods, exposed to CAP for different time intervals, and the
number of surviving cells was estimated by CFU counting. The
biofilm of the non-pathogenic B. subtilis was clearly the most
sensitive, with a strong initial drop of viability by almost two
orders of magnitude, followed by a saturated response (final
survival after 60 min was 0.5%; Figure 1A). E. coli and S.
epidermidis also showed a significant drop of viability after 5–
10 min of treatment, followed by saturation, but their residual
resistance to CAP was much higher, with 10–15% of cells
surviving after 60 min (Figures 1B,D). Finally, P. aeruginosa
exhibited a smaller initial decrease in viability, followed by a
significant drop after 30 min, leading to a survival of only 0.3%
of cells after 60 min of exposure (Figure 1C). The viability of B.
subtilis was reduced by 2.3 log after 30 min of CAP exposure,
which is similar to 5 min of CAP exposure. The viability of E. coli
was reduced by 0.9 log after 30 min of CAP exposure, which is
similar to 5 min of CAP exposure. The viability of S. epidermidis
was reduced by 0.8 log after 30 and 60 min of exposure. The
viability of P. aeruginosa was reduced by 0.6 and 2.5 log after 30
and 60 min of CAP exposure respectively (Table 1).
To confirm these findings by an independent method,
we examined the treated biofilms with live/dead staining
using fluorescence microscopy. Figure 2 shows the live/dead
fluorescent staining images of all the tested bacterial species after
a 30-min CAP exposure. B. subtilis biofilm was confirmed as
by far the most sensitive to a 30-min exposure. S. epidermidis,
E. coli, and P. aeruginosa biofilms were far more resistant,
as expected from the CFU counts. The morphology of the
CAP-treated bacteria was examined by SEM. Figure 3 shows
SEM images of control samples and samples after a 30-min
CAP exposure. Rupture of the bacterial cell membrane can be
clearly observed in all treated samples (Figure 3). Pronounced
morphological changes were visible in CAP exposed bacterial
biofilm. S. epidermidis in particular exhibited cell fragmentation
and disruption in cell structure typical for ROS-induced stress (Li
et al., 2016). Most importantly, biofilms of pathogenic bacteria
were not completely annihilated even after a 60 min treatment,
which is a very long time in terms of medical treatment.
Vitamin C Pre-treatment Strongly
Enhances the Bactericidal Effect of CAP
In order to test our hypothesis that vitamin C may enhance the
antibacterial effect of CAP treatment, we pre-treated the biofilm
samples with 5 mM ascorbate, for 15 min. After this, the biofilms
were treated with CAP for 5 min, which is an acceptably short
interval for most medical treatments (Isbary et al., 2010; Wu
et al., 2016). Figure 4 shows the comparison of the number
of CFUs in control samples that received only the 5-min CAP
exposure, the 15-min vitamin C treatment, and both treatments
subsequently (vitamin C followed by CAP). Mild decrease in
viability of biofilm bacteria was observed with only 5 min of CAP
exposure despite the clear synergistic effect was observed with
the pretreatment of vitamin C against all pathogen (Figure 4).
Vitamin C pretreatment enhances the bactericidal effect of cold
plasma by reducing the viability from 10 to 2% in E. coli biofilm,
50 to 11% in P. aeruginosa, and 61 to 18% in S. epidermidis biofilm
(Figure 4). Table 1 shows the comparison in log reduction in
bacterial viability with vitamin C pretreatment and cold plasma
exposure. The pretreatment with vitamin C enhances the log
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 3 February 2017 | Volume 7 | Article 43
Helgadóttir et al. Vitamin C Enhances Antibacterial Effect of CAP
FIGURE 1 | The loss of viability (log scale) for B. subtilis (A), E. coli (B), P. aeruginosa (C), and S. epidermidis (D) after cold atmospheric plasma (CAP) exposure
times of 5, 10, 15, 30, and 60 min compared to control samples. The % of viable bacteria was calculated by dividing the total number of bacteria counted in treated
sample with total number of bacteria counted in control. All experiments were performed in biological triplicates, the data represent the mean values ± standard
deviation. *P < 0.05, n/s is not significant.
TABLE 1 | The comparison of the log reduction after cold atmospheric plasma (CAP) exposures from 5 to 60 min, a 15-min vitamin C treatment, 15 min
di-H2O + 5 min CAP, and a combined treatment of vitamin C for 15 min followed by a 5-min CAP.
Bacterium 15-min vitamin C# 15 min di-H2O + 5 min CAP
# CAP + VC# 5-min CAP& 15-min CAP& 30-min CAP& 60-min CAP&
B. subtilis 1.0 1.9 2.1 2.0 2.0 2.3 x
S. epidermidis 0.3 0.2 0.8 0.1 0.6 0.8 0.8
E. coli 0.8 1.0 1.7 1.0 1.1 0.9 0.9
P. aeruginosa 0.4 0.3 1.5 0.4α 0.6 0.6 2.5
B. subtilis was not treated for 60 min. #Data were obtained in compared to 15 min di-H2O exposed control (from Figure 4). &Data were obtained in compared to general control (from
Figure 1). αP. aeruginosa was enhanced by 0.4 log.
reduction from 0.1 to 0.8 for S. epidermidis, 1.0 to 1.7 for E.
coli, and 0.4 to 1.5 (Table 1). In the case of B. subtilis, which is
inherently very sensitive to CAP, no significant improvement in
bactericidal effect was observed. For all the facultative pathogens,
the CAP bactericidal effect was enhanced three- to five-fold by
the vitamin C pre-treatment. SEM images of S. epidermidis after
the individual and combined treatment with vitamin C and CAP
are shown in Figure 5. A significantly higher level of structural
damage and rupture of the cell membrane was observed in the
sample that underwent the combined treatment, compared to
only 5 min CAP exposure and 15 min vitamin C treatment
(Figure 5, insets).
DISCUSSION
CAP has emerged as a useful tool for treating local microbial
infections and decontamination of various biomedical surfaces
(Cahill et al., 2014; Flynn et al., 2015). Previous studies
have demonstrated complete eradication of planktonic bacteria
after a couple of minutes of CAP treatment (Yu et al.,
2006; Flynn et al., 2015). Several studies have also tested the
efficacy of cold plasma against the bacterial biofilm (Ermolaeva
et al., 2011; Flynn et al., 2015). Their results suggested that
bacterial biofilms are more resistant to CAP, and there is
a need to increase the duration of exposure for complete
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FIGURE 2 | Live/dead fluorescent staining of B. subtilis, E. coli, P. aeruginosa, and S. epidermidis control samples and after a 30-min cold atmospheric
plasma (CAP) exposure. Green stained are live cells and red stained are dead cells. All experiments were performed in biological triplicates.
FIGURE 3 | SEM images of B. subtilis, E. coli, P. aeruginosa, and S. epidermidis control samples and after a 30-min cold atmospheric plasma (CAP)
exposure. Three individual samples were examined, and the figures show a representative sample. Red arrows indicate the membrane disruption.
decontamination. However, there are no studies regarding the
long term cold plasma exposure. Biofilms are considered to
be up to 1,000 times more resistant than the planktonic state
of bacteria, and it accounts for 60% of human infections,
with a high probability of becoming resistant to antimicrobials
(Mai-Prochnow et al., 2015). In this study we evaluated the
anti-biofilm activity of long term CAP exposure (5–60 min)
against four different bacterial strains, one non-pathogenic and
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FIGURE 4 | The number of CFU after a 5-min cold atmospheric plasma (CAP) treatment, a 15-min vitamin C treatment, and the synergistic effect of
15-min vitamin C treatment followed by a 5-min CAP treatment for B. subtilis (A), E. coli (B), P. aeruginosa (C), and S. epidermidis (D). The % of viable
bacteria was calculated by dividing the total number of bacteria counted in treated sample with total number of bacteria counted in control. All experiments were
performed in biological triplicates, the data represent the mean values ± standard deviation. *P < 0.05, n/s is not significant. #, biofilm treated with di-H2O for 15 min;
§, biofilm treated for 15 min with di-H2O + 5 min with CAP; &, biofilm treated with vitamin C for 15 min; β, biofilm treated for 15 min with vitamin C + 5 min with CAP.
FIGURE 5 | SEM images of S. epidermidis samples, after a 5-min cold atmospheric plasma (CAP) exposure, after a 15-min vitamin C treatment, and
after a treatment with vitamin C for 15 min followed by a 5-min CAP. Three individual samples were examined, and the figures show a representative sample.
three facultative pathogens. Furthermore, we also evaluated
whether vitamin C pre-treatment could be used to shorten
the duration of the CAP treatment while achieving the same
effect.
The response to CAP exposure for both the Gram-negative
and Gram-positive bacteria seems to be species dependent. As
shown in the Figure 1 and Table 1, non-pathogenic B. subtilis is
highly sensitive to CAP exposure, dropping to under 2% survival
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 6 February 2017 | Volume 7 | Article 43
Helgadóttir et al. Vitamin C Enhances Antibacterial Effect of CAP
after 5 min. E. coli and S. epidermidis were remarkably resistant
to CAP treatment. These results indicated that biofilms of E. coli,
P. aeruginosa, and S. epidermidis tend to be more resistant to
CAP compared to B. subtilis, and that different biofilm matrix
compositions, which are species-specific, can play a significant
role in CAP resistance. The initial viability drop occurred after
5 min of treatment, but then saturation ensued, and the biofilms
exhibited as much as 10–15% live bacteria even after 60 min of
treatment. P. aeruginosa was almost completely eradicated after
a 60-min exposure, but its inactivation curve was different. The
biofilm survived quite well up to 30 min of treatment, and then
the viability dropped radically from 30 to 60 min.
Such “two-slope” inactivation curves were reported previously
for biofilm inactivation (Joaquin et al., 2009). The first killing
phase corresponds to fast destruction of the top layers of the
biofilm, and is followed by the slower destruction of the bottom
layers, which are covered by dead cells and exopolysaccharide
biofilm matrix. It was also reported that the CAP treatment
triggers the bacterial cell entry into a viable-but-non-cultivable
(VBNC) survival state during the initial drop in the inactivation
curve, followed by the second phase in which the cells are actually
killed. The VBNC state has been reported for many Gram-
negative bacteria, which undergo morphological changes and
decrease in size (Joaquin et al., 2009).
Since the CFU method does not differentiate the dead cells
from the ones in the VBNC state, it is important to combine it
with other methods for confirmation. Our live/dead fluorescent
staining images (Figure 2) confirm the 30-min results of the
CFU counting, with B. subtilis being most sensitive, and the
three facultative pathogens comparably more resistant. Taken
together, the CFU counts and live/dead staining suggest that a
large portion of P. aeruginosa cells might be in the VBNC state
up to 30 min of exposure, and are finally killed after 60 min.
For all the tested facultative pathogens, a 5min CAP treatment
(which is a feasible duration for medical treatments) did not
efficiently eliminate the biofilm. The survival after 5 min of
CAP treatment was 25% for E. coli, 65% for S. epidermidis,
and 100% for P. aeruginosa (Figure 1). Since the bactericidal
effect of CAP is based on oxidative stress due to generation of
ROS, we investigated whether the efficiency of CAP could be
enhanced by pre-treatment with other ROS-generating agents
known to be harmless to humans. Vitamin C, an important
dietary supplement for humans, also has been demonstrated to
enhance the antimicrobial activity of several antimicrobial agents
(Cursino et al., 2005; Khameneh et al., 2016). Therefore, we
pre-treated the biofilms for 15 min with 5 mM vitamin C, also
known to generate ROS in most bacterial cells (Vilchèze et al.,
2013). The result was very encouraging. Vitamin C alone lead to
some loss of viability, but most importantly, when followed by
a 5 min CAP treatment, the viability of biofilms was reduced to
only 1.9% for E. coli, 17.6% for S. epidermidis, and 10.7% for P.
aeruginosa (Figure 4). This was a dramatic improvement (three-
to five-fold) over the 5 min CAP treatment alone. Our results
indicate that in combination with vitamin C, a very short CAP
exposure can be efficient against resilient biofilms of bacterial
pathogens. The powerful synergistic effect of CAP combined with
vitamin C is clearly visible in the Figure 5, where the treatment
is affecting the membrane integrity. Vitamin C treated cells were
more susceptible to collapsing during sample processing and as
a result more altered S. epidermidis cells were observed followed
by complete disintegration of cellular structure after subsequent
exposure to cold plasma. The pretreatment with vitamin C might
show great impact on current CAP based treatment strategy
such as wound and root canal treatment by enhancing the
bactericidal effect. In vivo studies are needed to evaluate the effect
of proposed combined treatment on real multispecies biofilm
consortium.
Overall, our results suggest that a brief pre-treatment with
vitamin C, followed by a very short CAP treatment could be a
viable route for treating various types of infectious lesions.
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